GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Praxis Precision Medicines Inc (NAS:PRAX) » Definitions » Asset Turnover

PRAX (Praxis Precision Medicines) Asset Turnover : 0.02 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Praxis Precision Medicines Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Praxis Precision Medicines's Revenue for the three months ended in Dec. 2024 was $7.46 Mil. Praxis Precision Medicines's Total Assets for the quarter that ended in Dec. 2024 was $449.68 Mil. Therefore, Praxis Precision Medicines's Asset Turnover for the quarter that ended in Dec. 2024 was 0.02.

Asset Turnover is linked to ROE % through Du Pont Formula. Praxis Precision Medicines's annualized ROE % for the quarter that ended in Dec. 2024 was -56.69%. It is also linked to ROA % through Du Pont Formula. Praxis Precision Medicines's annualized ROA % for the quarter that ended in Dec. 2024 was -52.20%.


Praxis Precision Medicines Asset Turnover Historical Data

The historical data trend for Praxis Precision Medicines's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Praxis Precision Medicines Asset Turnover Chart

Praxis Precision Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial - - - 0.02 0.03

Praxis Precision Medicines Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - 0.02

Competitive Comparison of Praxis Precision Medicines's Asset Turnover

For the Biotechnology subindustry, Praxis Precision Medicines's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Praxis Precision Medicines's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Praxis Precision Medicines's Asset Turnover falls into.


';

Praxis Precision Medicines Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Praxis Precision Medicines's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=8.553/( (87.948+483.11)/ 2 )
=8.553/285.529
=0.03

Praxis Precision Medicines's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=7.463/( (416.256+483.11)/ 2 )
=7.463/449.683
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Praxis Precision Medicines  (NAS:PRAX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Praxis Precision Medicines's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-234.716/414.058
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-234.716 / 29.852)*(29.852 / 449.683)*(449.683/ 414.058)
=Net Margin %*Asset Turnover*Equity Multiplier
=-786.27 %*0.0664*1.086
=ROA %*Equity Multiplier
=-52.20 %*1.086
=-56.69 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Praxis Precision Medicines's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-234.716/449.683
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-234.716 / 29.852)*(29.852 / 449.683)
=Net Margin %*Asset Turnover
=-786.27 %*0.0664
=-52.20 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Praxis Precision Medicines Asset Turnover Related Terms

Thank you for viewing the detailed overview of Praxis Precision Medicines's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Praxis Precision Medicines Business Description

Traded in Other Exchanges
N/A
Address
99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Executives
Alex Nemiroff officer: General Counsel and Secretary C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Lauren Mastrocola officer: Principal Accounting Officer C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Marcio Souza officer: Chief Executive Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Dean J Mitchell director C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Timothy Edwin Kelly officer: Chief Financial Officer C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bsof Parallel Master Fund L.p. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Merit Ester Cudkowicz director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Jeffrey Chodakewitz director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Stefan Vitorovic director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Blackstone Holdings I/ii Gp L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
William D Young director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Group Management L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154